Phase II Data On Saquinavir
A combination of Roche's proteinase inhibitor saquinavir (Ro31-8959), Wellcome's Retrovir (zidovudine) and Hoffmann-La Roche's Hivid (zalcitabine) demonstrated more effectiveness with respect to parameters such as CD4 counts than a combination of saquinavir and Retrovir or Retrovir and Hivid, according to a study conducted at Harborview Medical Center in Washington, USA.
The randomized, double-blind trial involved 302 HIV-positive subjects with CD4 cell counts between 51/mm3 and 300/mm3. The period of administration for the drug was 24 weeks. According to the researchers, the three-drug combination was the most effective therapy in the maintenance of CD4 levels. No difference in adverse reactions were observed among the three regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze